Tiziana Life Sciences (TLSA) Receivables - Net (2017 - 2022)

Tiziana Life Sciences (TLSA) has reported Receivables - Net for 6 consecutive years, with $300000.0 the latest figure, recorded in Q4 2022.

• Quarterly Receivables - Net fell 76.94% year-over-year to $300000.0 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $300000.0 (down 76.94% YoY) and the FY2022 annual result came in at $300000.0, down 76.94% from the prior year.
• Receivables - Net slipped to $300000.0 in Q4 2022 per TLSA's latest filing, from $1.3 million in the prior quarter.
• Over the last five years, Receivables - Net for TLSA reached as high as $1.3 million in Q4 2021 and fell as low as $165000.0 in Q4 2019.
• A 5-year average of $724000.0 and a median of $785000.0 in 2020 frame the typical range for Receivables - Net.
• Annual changes were most pronounced in 2019 — Receivables - Net slumped 84.57% — and 2020, when it surged 375.76%.
• Year by year, Receivables - Net stood at $1.1 million in 2018, then sank by 84.57% to $165000.0 in 2019, then jumped by 375.76% to $785000.0 in 2020, then soared by 65.73% to $1.3 million in 2021, then tumbled by 76.94% to $300000.0 in 2022.
• According to Business Quant data, Receivables - Net over the past three periods registered $300000.0, $1.3 million, and $785000.0 for Q4 2022, Q4 2021, and Q4 2020 respectively.